Cardiovascular Systems

Cardiovascular Systems (CSI) is a medical device company. CSI is focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Interventional endovascular treatment of peripheral artery disease (PAD) is the Company’s initial area of focus. The Company’s primary products include the Diamondback 360 PAD System (Diamondback 360), Diamondback Predator 360 PAD System (Predator 360) and Stealth 360 PAD System (Stealth 360). Diamondback 360, the Predator 360 and the Stealth 360 collectively are referred to as PAD Systems. As of June 30, 2011, the PAD Systems had been utilized in more than 50,000 procedures. It uses internally manufactured and externally sourced to manufacture the PAD Systems. In addition to the PAD Systems, CSI is expanding its product portfolio through internal product development and establishment of business relationships with other medical device companies.

Type
Public
HQ
Saint Paul, US
Size (employees)
597 (est)+26%
Cardiovascular Systems is headquartered in Saint Paul, US

Key People at Cardiovascular Systems

David L. Martin

David L. Martin

President & CEO
Laurence L. Betterley

Laurence L. Betterley

CFO
Scott Bartos

Scott Bartos

Director
Robert J. Thatcher

Robert J. Thatcher

Chief Healthcare Policy Officer
James E. Flaherty

James E. Flaherty

CAO
Glen D. Nelson

Glen D. Nelson

M.D. | Chairman of the Board

Cardiovascular Systems Office Locations

Cardiovascular Systems has offices in Saint Paul, Rochester
Saint Paul, US
Saint Paul, US
Rochester, US

Cardiovascular Systems Metrics

Cardiovascular Systems Summary

Market capitalization

$952 M

Closing share price

$28.4
Cardiovascular Systems's current market capitalization is $952 M.

Cardiovascular Systems Financials

Cardiovascular Systems's revenue is $178 M in FY, 2016 which is 1.85% decrease from the previous period.
FY, 2016FY, 2015FY, 2014

Revenue

$178 M$182 M$137 M

Revenue growth, %

-1.9%32.9%

Gross profit

$143 M$142 M$106 M

Operating income

$-56.1 M$-32.6 M$-33.5 M

Operating expense total

$199 M$175 M$139 M

Net Income

$-56 M$-32.8 M$-35.3 M

Operating cash flow

$-23.2 M$-42.8 M$58.7 M

Cardiovascular Systems Market Value History

Cardiovascular Systems News

Cardiovascular Systems Company Life

You may also be interested in